Trillium Therapeutics Inc (TRIL)

[NY1972]

In the TTI-621/rituximab combination cohort, 3 of 6 patients who have had at least one interval PET/CT restaging obtained partial metabolic responses, as demonstrated by decreased tumor activity on PET/CT scans. These patients with CD20-positive, B-cell lymphoma received weekly IV infusions of TTI-621 and rituximab. Manageable infusion reactions occurred in most patients after the first infusion of TTI-621 and the combination therapy has been associated with acceptable outpatient tolerability. These responding patients remain on treatment and progression-free for 19+ (DLBCL), 18+ (transformed lymphoma), and 8+ weeks (follicular lymphoma) in continuing follow-up.

http://trilliumtherapeutics.com/investors/news/Press-Release-Details/2017/Trillium-Therapeutics-Presents-TTI-621-Preclinical-Data-At-AACR-Annual-Meeting-And-Provides-Clinical-Update/default.aspx